Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
IMIPENEM; CILASTATIN (CILASTATIN SODIUM)
MERCK CANADA INC
J01DH51
IMIPENEM AND CILASTATIN
500MG; 500MG
POWDER FOR SOLUTION
IMIPENEM 500MG; CILASTATIN (CILASTATIN SODIUM) 500MG
INTRAVENOUS
25 VIALS (100 OR 250 ML)
Prescription
CARBAPENEMS
Active ingredient group (AIG) number: 0218820001; AHFS:
MARKETED
2006-12-13
_ _ _PRIMAXIN_ _®_ _ (imipenem and cilastatin sodium for injection, USP) _ _Page 1 of 61 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PRIMAXIN® imipenem and cilastatin for injection, USP 500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial Sterile powder for solution, I.V. Infusion ANTIBIOTIC Merck Canada Inc. 16750 route Transcanadienne Kirkland QC Canada H9H 4M7 www.merck.ca Date of Initial Authorization: JUL 07,1987 Date of Revision: DEC 21, 2021 Submission Control Number: 253551 _ _ _PRIMAXIN_ _®_ _ (imipenem and cilastatin sodium for injection, USP) _ _Page 2 of 61 _ RECENT MAJOR LABEL CHANGES 4. DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 12/2021 4. DOSAGE AND ADMINISTRATION 06/2020 7. WARNINGS AND PRECAUTIONS 06/2020 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . [To update, right-click anywhere in the Table of Contents and select “Update Field”, “Update entire table”, click OK.] RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 5 1 INDICATIONS .............................................................................................................. 5 1.1 Pediatrics ....................................................................................................................... 6 1.2 Geriatrics ....................................................................................................................... 6 2 CONTRAINDICATIONS ................................................................................................. 6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 7 4 DOSAGE AND ADMINISTRATION ................ Belgenin tamamını okuyun